Abstract:Objectives Docosahexaenoic acid (DHA) is routinely recommended to adequate fetal development during gestation. Since it is a substance with intense anti‐inflammatory action, its effects upon the fetal heart and circulation are unknown and safety of its administration during gestation is not yet established. This randomized clinical trial was designed to investigate if maternal supplementation of DHA is followed by alterations of maternal prostaglandin levels and fetal ductus arteriosus flow dynamics, at the final trimester of pregnancy. Methods A double blind, placebo‐controlled, randomized clinical trial by parallel groups was designed. The study was developed in the period of 2018 to 2021. Pregnant women above 18 years of age, at 27 or 28 weeks without cardiac alterations at fetal echocardiography were enlisted to the trial, with exclusion of those taking substances with known prostaglandin inhibition effect, such as nonsteroidal anti‐inflammatory drugs and polyphenol‐rich foods. The intervention group received oral supplementation of omega‐3 with 450 mg/day of DHA, and the placebo group received capsules of soy lecithin. Both groups were supplemented for eight weeks. The following data were obtained at the beginning and at the end of the follow‐up: anthropometric, assessment of polyphenol and omega‐3 consumption, fetal morphological ultrasound, fetal Doppler echocardiographic examination and blood draw to assess prostaglandin levels. Participants were considered eligible, without cardiac or extracardiac abnormalities, when the diagnosis of ductal constriction was excluded by two observers. Intergroup and intragroup data were evaluated. Results The study ended up with 24 participants in each group. After 8 weeks, Doppler echocardiographic parameters of ductal flow and serum prostaglandin levels in both groups did not show significant intergroup differences. The expected intragroup differences as a result in increase in gestational ages were present. Conclusions Even though complete safety of DHA has not been tested, this randomized clinical trial shows that third trimester maternal supplementation of DHA, at the doses and period used, does not result in inhibition of PGE2 and does not cause ductus arteriosus constriction, providing the basis for post‐market surveillance studies with larger numbers, to allow the best clinical reassurance. This article is protected by copyright. All rights reserved.

Oral docosahexaenoic acid supplementation and retinopathy of prematurity: The JoiDHA Clinical Trial

Docosahexaenoic Acid and Sleep Quality in Very and Extreme Preterm Infants

Maternal Omega-3 PUFA Supplementation Prevents Hyperoxia-Induced Pulmonary Hypertension in the Offspring

Nutritional interventions to prevent retinopathy of prematurity

Study protocol of OmegaROP-2 prospective study: expression of placental fatty acid receptors in preterm newborns with retinopathy of prematurity

Maternal high-dose docosahexaenoic acid supplementation and neurodevelopment at 5 Years of preterm children

Supplementation with a Highly Concentrated Docosahexaenoic Acid (DHA) in Non-Proliferative Diabetic Retinopathy: A 2-Year Randomized Double-Blind Placebo-Controlled Study

Maternal supplementation of DHA does not cause fetal ductus arteriosus constriction: randomized controlled trial

Retinopathy of Prematurity in Eight Portuguese Neonatal Intensive Care Units: Incidence, Risk Factors, and Progression-A Prospective Multicenter Study

Docosahexaenoic Acid Supplementation for Neonatal Hyperbilirubinemia: A Double-Blind, Randomized Clinical Trial

Lutein supplementation and retinopathy of prematurity: a meta-analysis

DHA, nutrient intake, and maternal characteristics as predictors of pregnancy outcomes in a randomised clinical trial of DHA supplementation

Arachidonic and docosahexaenoic acid supplementation and brain maturation in preterm infants; a double blind RCT

Effect of Optimizing Oxygen Saturation Targets on the Incidence of Retinopathy of Prematurity in a Quaternary NICU

Hyperbilirubinemia and retinopathy of prematurity: a retrospective cohort study

Soluble epoxide hydrolase promotes astrocyte survival in retinopathy of prematurity

The association between serum 25-hydroxyvitamin D levels and retinopathy of prematurity in preterm infants

[Evaluation of Risk Factors for Retinopathy of Prematurity].

Docosahexaenoic Acid Supplementation in Gestational Diabetes Mellitus and Neonatal Metabolic Health Biomarkers

Potential Effects of Nutraceuticals in Retinopathy of Prematurity

Increased risk of retinopathy of prematurity since increased O2 saturation targets: A multi-centre study